Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compounds for treating parvovirus infection

A technology of parvoviruses and compounds, applied in the field of compounds, can solve problems such as amantadine treatment or prevention of parvovirus infections that have not been proposed

Inactive Publication Date: 2014-12-17
阿拉塔纳医疗有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of amantadine for the treatment or prevention of parvovirus infection has not been suggested in the art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for treating parvovirus infection
  • Compounds for treating parvovirus infection
  • Compounds for treating parvovirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] Example 1: Through amantadine, amantadine hydrochloride (HCl), 2-adamantylamine HCl, 3-amino-1-adamantanol (amantadol), N-methyl-1-adamantyl Amine, 1-adamantylmethylamine, rimantadine, and memantine inhibit feline panleukopenia virus and canine parvovirus 2c replication in cell culture

[0120] Materials and methods

[0121] Add amantadine, amantadine HCl, 2-adamantylamine HCl, 3-amino-1-adamantyl alcohol (amantadol), N-methyl-1-adamantylamine, 1-adamantylamine at a concentration of 10 mM Alkylmethylamines, rimantadine and memantine were dissolved in Dulbecco's phosphate buffered saline (DPBS). Crandell Reese feline kidney (CrFK) cells were grown in Dulbecco's minimal essential medium containing 1% sodium bicarbonate (Life Technologies), 1% L-glutamine (Life Technologies), and 5% fetal calf serum (FCS, Biochrom) (DMEM, Life Technologies). Add serial dilutions of compounds along with 10 TCID in a 96-well plate 50 Feline panleukopenia virus (FPV) or 10TCID 50 Canin...

Embodiment 2

[0126] Example 2: Inhibition of feline panleukopenia virus and canine parvovirus 2c production and viral DNA production in cell culture by amantadine, amantadine hydrochloride (HCl) and memantine.

[0127] Materials and methods

[0128] Amantadine, amantadine hydrochloride (HCl) and memantine were dissolved in Dulbecco's phosphate buffered saline (DPBS) at a concentration of 10 mM. Crandell Reese feline kidney (CrFK) cells were cultured in Dulbecco's minimal essential medium containing 1% sodium bicarbonate (Life Technologies), 1% L-glutamine (Life Technologies), and 5% fetal calf serum (FCS, Biochrom) (DMEM, Life Technologies). 100,000 CrFK cells were seeded in 24-well plates on day 0. On day 1, remove medium and add 10 TCID 50 FPV or 10TCID 50 CPV-2c and incubated for 2 h at 37°C under humidified conditions. After incubation, the medium was removed and the CrFK cells were washed with DPBS. Subsequently, serial dilutions (250, 50 and 10 [mu]M) of the compound in the m...

Embodiment 3

[0138] Example 3: Inhibition of feline panleukopenia virus and canine parvovirus 2c production in cell culture by 2-methyladamantan-2-amine hydrochloride and 2-ethyladamantan-2-amine hydrochloride and viral DNA production.

[0139] 2-Methyladamantan-2-amine HCl and 2-ethyladamantan-2-amine HCl were dissolved in Dulbecco's phosphate buffered saline (DPBS) at a concentration of 10 mM. Its inhibition experiments and preparation were performed as described above for Example 2.

[0140] 2-Methyladamantan-2-amine HCl and 2-Ethyl Glycine effectively inhibited 50% of FPV and CPV-2c virus and DNA production as determined by cytopathic effect (CPE) visual scoring and measured by quantitative PCR The concentration of adamantane-2-amine HCl (EC 50 ) are given in Table 4a and Table 4b, respectively. Both 2-methyladamantan-2-amine HCl and 2-ethyladamantan-2-amine HCl were found to be very effective in reducing viral DNA.

[0141] Table 4a - EC in μM for antiviral activity of compounds a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to compounds for use in a method for the treatment or prevention of parvovirus infections in humans and warm-blooded animals, including feline panleukopenia virus (FPV) infections in felids, canine parvovirus type 2 (CPV-2) infections in canines, minute virus of mice (MVM) infections in mice and B19 parvovirus infections in humans.

Description

field of invention [0001] The present invention relates to compounds useful in the treatment or prevention of parvovirus infections in humans and warm-blooded animals, including feline panleukopenia virus (FPV) infections in felines, canines The methods of canine parvovirus type 2 (CPV-2) infection in mice, mouse parvovirus (Minute Virus of Mice) (MVM) infection in mice and B19 parvovirus infection in humans were used. Background of the invention [0002] Parvoviruses (family Parvoviridae) are small, non-enveloped, single-stranded DNA viruses that are usually species-specific. The family Parvoviridae is divided into the following subfamilies: Densovirinae, which infects only invertebrates, and Parvovirinae, which infects vertebrates. The Parvovirus subfamily is divided into the following genera: Amdovirus, Bocavirus, Dependovirus, Erythrovirus, and Parvovirus. In humans, human parvovirus B19 is the only member of the family Parvoviridae known to cause disease. The B19 par...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/13A61P31/12A61P31/20
CPCA61K31/13A61P31/12A61P31/20C07C211/38
Inventor 内斯亚·戈里斯约翰·内茨埃尔温·布洛姆萨斯特凡·韦拉热罗姆·维莱尔艾诺·比耶约里·奥威尔克斯维尔勒·德伯梅埃莱奥诺拉·基斯克洛艾·斯温嫩
Owner 阿拉塔纳医疗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com